| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Complement component C3 (as a negative control, it does not bind or inhibit C3). Compstatin control peptide is a negative control for compstatin, which itself is a potent inhibitor of the complement system C3. Unlike the active compstatin, this control peptide does not bind to or inhibit cleavage of complement C3. It is used to distinguish specific complement inhibition by compstatin from non-specific peptide effects.
|
|---|---|
| ln Vitro |
As a negative control peptide, Compstatin control peptide does not exhibit complement-inhibitory activity in vitro. The active compstatin peptide is a potent complement C3 inhibitor, but this control peptide is designed to lack such activity. It is used as a baseline in assays to confirm that observed complement inhibition is specifically due to compstatin and not to non-specific peptide effects.
|
| ln Vivo |
Compstatin control peptide is used as a negative control in in vivo studies involving complement inhibition. It does not exert therapeutic effects. In contrast, active compstatin has been shown to prolong the survival of ex vivo perfused pig xenografts. This control peptide serves to validate the specificity of compstatin's in vivo effects.
|
| Enzyme Assay |
Non-cell-based assays for Compstatin control peptide typically involve complement binding or activity assays. The peptide is used as a negative control in experiments measuring complement component C3 cleavage or deposition. It is tested alongside active compstatin to demonstrate that the control peptide does not inhibit C3 cleavage, thereby validating the specificity of the active compound's mechanism of action.
|
| Cell Assay |
In cell-based complement assays, Compstatin control peptide is used as a negative control in systems such as neutrophil-like HL60 cells or whole blood models. Cells are treated with the control peptide alongside active compstatin to assess complement-dependent effects. The control peptide should not inhibit complement-mediated cellular responses, confirming that any observed inhibition is specifically due to compstatin.
|
| Animal Protocol |
In vivo animal studies using Compstatin control peptide are conducted in models such as ex vivo perfused pig xenografts, where active compstatin prolongs survival. The control peptide is administered as a negative control to demonstrate that any protective effects observed are specifically due to compstatin's complement inhibition and not to non-specific peptide effects.
|
| ADME/Pharmacokinetics |
Compstatin control peptide has a molecular weight of 1,488.67 g/mol and a molecular formula of C₆₆H₁₀₁N₂₃O₁₇. It is soluble to 1 mg/ml in water. The peptide should be stored at -20°C. It has a purity of >98% and appears as a white lyophilized solid. It is a control peptide for compstatin, a complement inhibitor.
|
| Toxicity/Toxicokinetics |
Compstatin control peptide is a negative control for the potent complement inhibitor compstatin and is not intended for therapeutic use. It is for research use only. The peptide has a sequence of IAVVQDWGHHRAT and is supplied as a white lyophilized solid. It is used to validate the specificity of compstatin-mediated complement inhibition in research applications.
|
| References |
[1]. Sahu A, et al. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol. 2000 Sep 1;165(5):2491-9.
|
| Additional Infomation |
Compstatin control peptide is a negative control for compstatin, which is a potent complement system C3 inhibitor. Compstatin itself is a peptide inhibitor of complement component C3 that has been studied for its potential in treating complement-mediated diseases. The control peptide is used in research to validate the specificity of compstatin's effects. It is not approved for therapeutic use and is intended for research purposes only.
|
| Molecular Formula |
C66H101N23O17
|
|---|---|
| Molecular Weight |
1488.65
|
| Exact Mass |
1487.774
|
| CAS # |
301544-78-5
|
| Related CAS # |
Compstatin control peptide TFA
|
| PubChem CID |
90488879
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.681
|
| LogP |
-3.22
|
| Hydrogen Bond Donor Count |
22
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
45
|
| Heavy Atom Count |
106
|
| Complexity |
3090
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
O=C([C@H](C(C)C)NC([C@H](C)NC([C@H]([C@@H](C)CC)N)=O)=O)N[C@H](C(N[C@H](C(N[C@@H](CC(=O)O)C(N[C@H](C(NCC(N[C@@H](CC1=CN=CN1)C(N[C@H](C(N[C@H](C(N[C@@H](C)C(N[C@H](C(N)=O)[C@@H](C)O)=O)=O)CCC/N=C(\N)/N)=O)CC1=CN=CN1)=O)=O)=O)CC1=CNC2C=CC=CC1=2)=O)=O)CCC(N)=O)=O)C(C)C
|
| InChi Key |
SAJZITDYWAOPDD-LSPMIEDISA-N
|
| InChi Code |
InChI=1S/C66H101N23O17/c1-10-32(6)50(68)63(104)80-34(8)55(96)87-52(31(4)5)65(106)88-51(30(2)3)64(105)83-42(17-18-47(67)91)59(100)86-46(23-49(93)94)62(103)84-43(20-36-24-75-40-15-12-11-14-39(36)40)57(98)76-27-48(92)81-44(21-37-25-72-28-77-37)60(101)85-45(22-38-26-73-29-78-38)61(102)82-41(16-13-19-74-66(70)71)58(99)79-33(7)56(97)89-53(35(9)90)54(69)95/h11-12,14-15,24-26,28-35,41-46,50-53,75,90H,10,13,16-23,27,68H2,1-9H3,(H2,67,91)(H2,69,95)(H,72,77)(H,73,78)(H,76,98)(H,79,99)(H,80,104)(H,81,92)(H,82,102)(H,83,105)(H,84,103)(H,85,101)(H,86,100)(H,87,96)(H,88,106)(H,89,97)(H,93,94)(H4,70,71,74)/t32-,33-,34-,35+,41-,42-,43-,44-,45-,46-,50-,51-,52-,53-/m0/s1
|
| Chemical Name |
(3S)-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 25 mg/mL (16.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6717 mL | 3.3587 mL | 6.7175 mL | |
| 5 mM | 0.1343 mL | 0.6717 mL | 1.3435 mL | |
| 10 mM | 0.0672 mL | 0.3359 mL | 0.6717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
